MENU
JUN 30, 2016 7:30 AM PDT

Proteome centric precision medicine: embracing pathological diversity

Speaker
  • Director, Advanced Clinical Biosystems Research Institute and Director of the Basic Science Research of the Barbra Streisand Woman's Heart Center
    BIOGRAPHY

Abstract
Precision medicine requires success in two intertwined aspects: precision therapy and personalized medicine. Precision therapy is being able to effectively treat the right disease; to have therapies that target for the correct pathological pathways.  Personalized medicine requires diagnosing a specific individual’s disease based on accurate assessment their complex health and pathological status. Our underlying premise is that an individual’s baseline proteome reflects their past and present and thus, will dictate their future health and disease. Thus, the crux of precision medicine will be the identification and precise quantification of proteins and their modified forms. We will present data to support the notion that an individual’s baseline proteome dictates the manifestation of their disease, its progression and their response to therapy. This concept has driven decision-making processes around new drug trials that take into account altered pathological proteomes.  Furthermore, this work has led us to consider the need for continuous patent-centric biomarker analysis at the population level. We will share our work on developing technical pipelines for health and pathological discovery and targeted proteomic analysis that reduces the barriers around gender, age and social economic status. We have begun down this path with production of system suitability and quality control measures, development of quantitative small and large multiplex assays and will discuss the remaining challenges involved and requirement for population-scale proteomics.

Learning Objectives:
  • Understand the underlying premise that an individual’s baseline proteome reflects their past and present and thus, will dictate their future health and disease
  • See data to support the notion that an individual’s baseline proteome dictates the manifestation of their disease, its progression and their response to therapy

Show Resources
You May Also Like
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
JUN 28, 2022 7:00 AM PDT
JUN 28, 2022 7:00 AM PDT
Date: June 28, 2022 Time: 3:00pm (BST), 4:00pm (CET), 9:00am (CST), 7am (PST) Light-sheet microscopy is an extremely versatile imaging technique with a vast range of implementations that are...
NOV 16, 2022 7:00 PM PST
C.E. CREDITS
NOV 16, 2022 7:00 PM PST
Date: November 16, 2022 Time: 2:00pm (AEST) Date: November 17, 2022 7:00pm (PST), 10:00pm (EST), 4:00am (CET) The growth in FDA-approved cell and gene therapy products for the treatment of d...
AUG 24, 2022 7:00 AM PDT
AUG 24, 2022 7:00 AM PDT
Date: August 24, 2022 Time: 7:00am (PDT), 10:00pm (EDT), 4:00pm (CEST) Light field microscopy was first introduced in 2006, and allows users to capture the 4D light field within the microsco...
OCT 26, 2022 9:00 AM PDT
OCT 26, 2022 9:00 AM PDT
Date: October 26, 2022 Time: 9:00am (PST), 12:00pm (EST), 6:00pm (CEST) Current protein biomarkers are only moderately predictive in identifying individuals with mild traumatic brain injury...
SEP 13, 2022 8:00 AM PDT
SEP 13, 2022 8:00 AM PDT
Date: September 13, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Preparedness against pandemic diseases demands rapid-response vaccine technology and ready-to-use analytical methods...
Loading Comments...
Show Resources